FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

Medical experts in India are calling for urgent attention to Respiratory Syncytial Virus (RSV), a highly contagious but under-discussed cause of lower respiratory tract infections in infants ...

Indian pediatric experts report that Respiratory Syncytial Virus (RSV) causes a significant number of infant respiratory ...

Citing Indian Council for Medical Research (ICMR) and published studies, Dr Bhavesh Kotak, Head of Medical Affairs at Dr ...

With high hospitalisation rates during monsoon and winter, experts urge timely action, expanded access to preventive care, ...

As Thailand transitions from the rainy to early winter seasons, respiratory infections surge dramatically, making awareness ...

US biotech major Gilead Sciences (Nasdaq: GILD) has halted two mid-stage studies of its experimental antiviral obeldesivir after low rates of respiratory syncytial virus (RSV) infections undermined ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health Secretary Robert F. Kennedy Jr. fired the entire panel and named eight new ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...

Once commercially launched, Merck’s Enflonsia will face stiff competition from AstraZeneca AZN/Sanofi’s SNY RSV antibody Beyfortus, which was also approved for a similar indication in 2023. This ...